Preview: Flex's Earnings
Flextronics International Ltd. FLEX | 0.00 |
Flex (NASDAQ:FLEX) is set to give its latest quarterly earnings report on Wednesday, 2024-01-31. Here's what investors need to know before the announcement.
Analysts estimate that Flex will report an earnings per share (EPS) of $0.61.
Flex bulls will hope to hear the company announce they've not only beaten that estimate, but also to provide positive guidance, or forecasted growth, for the next quarter.
New investors should note that it is sometimes not an earnings beat or miss that most affects the price of a stock, but the guidance (or forecast).
Historical Earnings Performance
Last quarter the company beat EPS by $0.10, which was followed by a 10.98% increase in the share price the next day.
Here's a look at Flex's past performance and the resulting price change:
| Quarter | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 |
|---|---|---|---|---|
| EPS Estimate | 0.58 | 0.51 | 0.51 | 0.55 |
| EPS Actual | 0.68 | 0.57 | 0.57 | 0.62 |
| Price Change % | 10.98% | -4.49% | 8.8% | -1.77% |

Stock Performance
Shares of Flex were trading at $23.05 as of January 29. Over the last 52-week period, shares are up 38.31%. Given that these returns are generally positive, long-term shareholders are likely bullish going into this earnings release.
To track all earnings releases for Flex visit their earnings calendar on our site.
This article was generated by Benzinga's automated content engine and reviewed by an editor.
Recommend
- Sahm Platform 19/11 09:29
How Investors Are Reacting To First American Financial (FAF) After Solel Partners’ Major New Stake and Dividend Boost
Simply Wall St 19/11 12:31Morgan Stanley Maintains Equal-Weight on Energizer Hldgs, Lowers Price Target to $22
Benzinga News 19/11 12:41Classiq and BQP Demonstrate Hybrid Quantum-Classical Breakthrough for Scalable Digital Twin and CFD Simulation with NVIDIA
Reuters 19/11 13:00GT Biopharma Advances Potent NK-Cell Therapies As GTB 3650, Is Currently Being Tested In Phase 1 Trials For Patients With Relapsed Or Refractory Acute Myeloid Leukemia
Benzinga News 19/11 13:09Should ICE’s (ICE) Launch of IRM 2 Transform Portfolio Risk Management for Energy Market Participants?
Simply Wall St 19/11 13:19Broadcom Struggles Amid Steep AI Correction, Raising Awareness Of Direxion's AVL, AVS ETFs
Benzinga News 19/11 13:26Everyone's Buzzing About Google's Gemini 3! What Are the Related U.S. Stock Investment Opportunities?
Sahm Platform 20/11 07:08


